PubRank

Elizabeth A Mittendorf

Author PubWeight™ 90.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013 3.38
2 Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 2012 2.40
3 Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2011 2.29
4 Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg 2011 2.16
5 Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010 2.12
6 Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 2011 1.93
7 Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009 1.89
8 Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010 1.79
9 Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010 1.70
10 Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol 2014 1.63
11 Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol 2011 1.44
12 Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 2011 1.42
13 Injecting Hope-A Review of Breast Cancer Vaccines. Oncology (Williston Park) 2016 1.39
14 The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009 1.38
15 Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 2010 1.35
16 Utility of laparoscopy in chronic abdominal pain. Surgery 2003 1.35
17 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008 1.33
18 Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2007 1.32
19 Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg 2016 1.30
20 American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol 2012 1.29
21 Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 2012 1.16
22 Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 2015 1.15
23 Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014 1.12
24 Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011 1.12
25 The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 2012 1.12
26 Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2010 1.11
27 Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol 2012 1.09
28 Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg 2012 1.09
29 Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 2011 1.08
30 Staging of breast cancer in the neoadjuvant setting. Cancer Res 2008 1.03
31 Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 2011 1.03
32 Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 2011 1.02
33 Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 2012 1.02
34 Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol 2010 0.99
35 Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study. Ann Surg Oncol 2007 0.98
36 A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 2010 0.97
37 Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008 0.97
38 Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2010 0.97
39 Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008 0.96
40 A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res 2012 0.95
41 Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012 0.94
42 The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother 2012 0.94
43 Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol 2013 0.94
44 Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer 2012 0.93
45 Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 2012 0.93
46 Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 2010 0.92
47 The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol 2012 0.92
48 Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys 2011 0.91
49 Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010 0.91
50 Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 2013 0.91
51 Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg 2012 0.90
52 Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010 0.88
53 Electrical impedance scanning as a new breast cancer risk stratification tool for young women. J Surg Oncol 2008 0.88
54 Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer 2013 0.88
55 Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 2012 0.87
56 AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther 2011 0.86
57 Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol 2013 0.86
58 Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother 2008 0.86
59 Folate receptor α: a storied past and promising future in immunotherapy. Hum Vaccin 2011 0.86
60 Landmark trials affecting the surgical management of invasive breast cancer. Surg Clin North Am 2013 0.85
61 Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 2011 0.85
62 Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. Cancer 2012 0.85
63 Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist 2013 0.84
64 Lymphatic interrupted: do we really understand the risks and consequences? Ann Surg Oncol 2009 0.83
65 Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines 2012 0.82
66 Gamma probe identification of normal parathyroid glands during central neck surgery can facilitate parathyroid preservation. Am J Surg 2008 0.81
67 The controversy regarding margin width in breast cancer: enough is enough. Ann Surg Oncol 2014 0.81
68 Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer. BioDrugs 2015 0.81
69 Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 2012 0.80
70 The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now? Ann Surg Oncol 2013 0.80
71 MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol 2012 0.79
72 Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2011 0.79
73 An elderly woman with primary hyperparathyroidism exhibits improvement of neurocognitive dysfunction after parathyroidectomy. J Am Geriatr Soc 2007 0.78
74 Clinical course of breast cancer patients with isolated sternal and full-thickness chest wall recurrences treated with and without radical surgery. Ann Surg Oncol 2013 0.78
75 Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg 2016 0.77
76 Controversies in breast surgery. Ann Surg Oncol 2010 0.77
77 Surgical considerations in patients receiving neoadjuvant systemic therapy. Future Oncol 2012 0.77
78 Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2015 0.77
79 Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 2010 0.77
80 Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol 2012 0.77
81 Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 2013 0.76
82 Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer 2011 0.76
83 Asymptomatic appendicolithiasis: principles of evaluation and management. Curr Surg 2005 0.75
84 Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol 2011 0.75
85 Following the data: past, present, and future management of the axilla in breast cancer patients. Oncology (Williston Park) 2014 0.75
86 Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 2016 0.75
87 Complications of low-molecular-weight heparin in surgical patients with impaired renal function. Curr Surg 2005 0.75
88 Maintenance of certification: what everyone needs to know. Ann Surg Oncol 2015 0.75
89 SLN surgery for clinically node-positive breast cancer patients treated with neoadjuvant therapy. Bull Am Coll Surg 2014 0.75
90 Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer 2010 0.75
91 Obese Women Experience Fewer Complications after Oncoplastic Breast Repair following Partial Mastectomy Than after Immediate Total Breast Reconstruction. Plast Reconstr Surg 2016 0.75
92 Management of giant gastric ulcers: case report and review of the literature. Curr Surg 2004 0.75
93 Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg 2017 0.75
94 Satisfaction with breast cancer screening and future screening participation. Med Sci Monit 2007 0.75